Results from a standard PRISM assay using the PR500 cell set suggested that the novel compound, XL177A, acts by USP7 inhibition and that sensitivity to USP7 inhibition is associated with the mutational status of TP53. This study also found two pediatric cancers, Ewing sarcoma, and malignant rhabdoid tumor, were sensitive to XL177A.